Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Inhibikase Therapeutics, Inc. (IKT) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.Equitrans Midstream Corporation (ETRN) : This midstream energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.7% over the last 60 days.ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus E ...

Since late last year, the healthcare sector has seen a steady rise. As of January, an otherwise indifferent month for the broad sectors other than tech and financials, health care advanced 3%, and is up 7.1% over the past 12 months.The sector is riding on investors' current bet on healthcare to emerge as one of the winners for 2024. As is, the regular demand for medical services is not dependent on the peaks and troughs of a market, especially one that has remained volatile with an eye on the Fed’s tight mo ...

Adma Biologics (ADMA) ended the recent trading session at $5.18, demonstrating a -1.71% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.82%. Meanwhile, the Dow experienced a rise of 0.41%, and the technology-dominated Nasdaq saw an increase of 0.95%.The infectious disease drug developer's shares have seen an increase of 3.94% over the last month, surpassing the Medical sector's gain of 3.2% and falling behind the S&P 500's gain of 5.59%.Market participants will b ...

经纪推荐 - 投资者在做出股票买入、卖出或持有决策之前通常会参考华尔街分析师的推荐[1] - Adma Biologics目前的平均经纪推荐（ABR）为1.00，表示强烈买入[2] - 经纪推荐趋势显示，虽然ABR建议购买Adma Biologics，但仅凭此信息做出投资决策可能不明智[4] - 经纪公司对所覆盖股票存在强烈的正面偏见，通常会给出更多“强烈买入”推荐[5] Zacks Rank - 经纪推荐与Zacks Rank不同，Zacks Rank是基于盈利预期修订的量化模型[9] - 经验研究表明，盈利预期修订与近期股价走势之间存在强烈相关性[11] - Zacks Rank对所有经纪分析师提供的当年盈利预期进行比例分配，保持五个等级之间的平衡[12] - Zacks Rank与ABR的另一个关键区别是及时性，Zacks Rank能够及时反映公司业务趋势变化的盈利预期修订[13] 公司盈利预期 - Adma Biologics当前年度盈利预期的Zacks Consensus Estimate在过去一个月内增长了26.4%至-0.02美元[14] - 分析师对公司盈利前景的乐观态度，以及他们在修订盈利预期方面的强烈一致性，可能是股票在短期内飙升的合理原因[15] - 最近一次共识预期变化的规模，以及与盈利预期相关的其他三个因素，导致Adma Biologics的Zacks Rank为2（买入）[16]

Shares of Adma Biologics (ADMA) have gained 18.9% over the past four weeks to close the last trading session at $5.23, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.88 indicates a potential upside of 31.6%.The average comprises four short-term price targets ranging from a low of $6 to a high of $9, with a standard deviation of $1.44. While the lowest estimate indicates an i ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.Inhibikase Therapeutics, Inc. (IKT) : This clinical-stage pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.YPF Sociedad Anónima (YPF) : This international energy company engaging in the ...

ADMA生物制品公司股票表现 - ADMA生物制品公司的股票在过去三个月中上涨了66.2%[1] 加拿大帝国商业银行股票表现 - 加拿大帝国商业银行的股票在过去三个月中上涨了29.5%[2] Turtle Beach公司股票表现 - Turtle Beach公司的股票在过去三个月中上涨了45.1%[3]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.Potbelly Corporation (PBPB) : This restaurant franchise company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.4% over the last 60 days.YPF Sociedad Anónima (YPF) : This energy company has seen the Zacks Consensus Estimate for its curren ...

ADMA生物制品公司股票表现 - ADMA生物制品公司的股票在过去四周上涨了21.6%，收盘价为$5.02[1] - ADMA目前拥有Zacks Rank 1（强烈买入），在盈利预期排名的4000多支股票中处于前5%[12] ADMA生物制品公司盈利前景 - 分析师们对ADMA公司的盈利前景持乐观态度，认为公司有望报告比之前预测的更好的收益[4] - 分析师们通常会设定过于乐观的价格目标，以激发对公司股票的兴趣，可能导致价格目标被夸大[7]

生物制品公司盈利预期增长 - ADMA生物制品公司的今年盈利预期在过去60天内增长了33.3%[1] - Arcutis生物制品公司的今年盈利预期在过去60天内增长了10.4%[1] - Phreesia公司的今年盈利预期在过去60天内增长了11.1%[1] - OptimizeRx公司的今年盈利预期在过去60天内增长了25%[1] - Koninklijke Philips公司的今年盈利预期在过去60天内增长了4.7%[1]